Immutep (IMMP) Receivables - Accured (2022 - 2023)
Immutep (IMMP) posted Receivables - Accured of $28985.4 for Q4 2023, up 105.8% on a QoQ basis from $14084.4 in Q2 2023, and up 4225.12% year-over-year from $670.16 in Q4 2022.
Immutep (IMMP) Receivables - Accured (2022 - 2023) Analysis & Trends
Immutep's Receivables - Accured history runs 2 years deep, the most recent figure standing at $28985.4 for Q4 2023.
- Quarterly Receivables - Accured rose 4225.12% year-over-year to $28985.4 in Q4 2023, while the trailing twelve-month figure through Dec 2023 was $28985.4 (up 4225.12% YoY) and the FY2023 annual result came in at $14084.4, up 45629.13% from the prior year.
- Receivables - Accured was $28985.4 for Q4 2023 at Immutep, up from $14084.4 in the prior quarter.
- Across five years, Receivables - Accured topped out at $28985.4 in Q4 2023 and bottomed at $30.8 in Q2 2022.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Receivables - Accured (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 67,072.09 Bn | 67,072.09 Bn | - | 1.53 Mn |
| 2 | Nanobiotix | 1,894.61 Bn | 1,894.55 Bn | - | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - | - |
| 4 | BeOne Medicines | 471.64 Bn | 466.85 Bn | 1.35 Bn | - |
| 5 | Vertex Pharmaceuticals | 121.72 Bn | 114.47 Bn | 2.59 Bn | - |
| 6 | Regeneron Pharmaceuticals | 68.28 Bn | 59.52 Bn | 3.31 Bn | - |
| 7 | Belite Bio | 61.40 Bn | 61.40 Bn | - | - |
| 8 | Argenx Se | 56.94 Bn | 56.94 Bn | 1.18 Bn | - |
| 9 | Revolution Medicines | 37.37 Bn | 37.37 Bn | - | - |
| 10 | Immutep | 569.08 Mn | 569.08 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2023 | 28,985.35 |
| Dec 31, 2023 | 28,985.35 |
| Jun 30, 2023 | 14,084.36 |
| Jun 30, 2023 | 14,084.36 |
| Dec 31, 2022 | 670.16 |
| Dec 31, 2022 | 670.16 |
| Jun 30, 2022 | 30.80 |
| Jun 30, 2022 | 30.80 |